One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C

Figure 1 Rates of patients with undetectable hepatitis B virus DNA through week 192. A: Proportion of patients with HBV DNA < 20 IU/mL in Group A and B in HBeAg positive (+) patients; B: Proportion of patients with HBV DNA < 20 IU/mL in Groups A and B in HBeAg negative (-) patients. HBeAg: Hepatitis B e antigen.

Figure 2 Rates of undetectable hepatitis B virus DNA levels in patients with different baseline hepatitis B virus DNA levels from 48 wk to 192 wk. HBV: Hepatitis B virus.

Figure 3 Rates of patients with hepatitis B e antigen loss and hepatitis B e antigen seroconversion, and alanine aminotransferase normalization through week 192. A: Percentage of patients with hepatitis B e antigen (HBeAg) loss in Groups A and B; B: Percentage of patients with HBeAg seroconversion in Groups A and B; C: Percentage of patients with alanine aminotransferase (ALT) normalization in Groups A and B in hepatitis B e antigen positive (+) patients; D: Percentage of patients with ALT normalization in Groups A and B in in HBeAg positive (+) patients. HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; ALT: Alanine transaminase.